Emalex Biosciences is focused on developing innovative treatments for central nervous system disorders, particularly Tourette syndrome (TS). The company is conducting late-stage clinical trials for ecopipam, a first-in-class dopamine-1 (D1) receptor antagonist. This investigational drug aims to reduce tic severity in children and adolescents with TS, offering a new therapeutic option for patients who have limited treatment alternatives. Ecopipam's mechanism of action involves blocking the effects of dopamine at the D1 receptor, which is believed to play a role in the repetitive and compulsive behaviors associated with TS. The drug has shown promise in clinical studies, demonstrating a favorable safety profile and receiving Orphan Drug and Fast Track designations from the FDA.

In addition to its focus on Tourette syndrome, Emalex is also exploring treatments for other neurological conditions, such as Restless Legs Syndrome with Augmentation (RLSa). The company is committed to addressing the needs of patients suffering from these disorders, as evidenced by its ongoing clinical trials and research initiatives. Emalex's dedication to advancing therapeutic options is underscored by its partnerships and commitment to patient resources, aiming to alleviate the social stigma and emotional distress often experienced by individuals with TS and related conditions.

United States

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Emalex Biosciences

Company Details